SKAN Group (SKAN) H1 2025 earnings summary

Executive summary

• Order intake grew 20.2% year-over-year to CHF 213 million, with a record order backlog of CHF 386.4 million, driven by strong demand for ADC filling lines and robust pipeline quality.

• Net sales declined 17.8% year-over-year to CHF 134.6 million, mainly due to project postponements in vaccine and GLP-1 lines, reflecting the cyclical business nature.

• EBITDA dropped sharply to CHF 0.9 million (down 95.7% year-over-year), with margin at 0.7%, reflecting lower sales, project phasing, and stable cost base.

• Strategic acquisitions (Metronik, ABC Transfer, Plast4Life) expanded digital and consumables offerings.

• Workforce grew to 1,504 employees, plus 181 from recent acquisitions.

Financial highlights

• Book-to-bill ratio at 1.6, providing strong sales visibility.

• Order backlog reached a record CHF 386.4 million, up 21% year-over-year.

• Free cash flow improved to CHF 9.2 million from -CHF 29.5 million year-over-year.

• Equity ratio stands at 48.1%, and net cash position is CHF 42.9 million.

• Gross margin improved to 79.8% due to favorable product mix.

Outlook and guidance

• Full-year 2025 guidance confirmed: mid-teens sales growth and EBITDA margin of 14%-16%.

• Second half expected to see higher sales and margin as postponed projects move into revenue-intensive phases.

• Guidance achievable with organic growth, with acquisitions providing additional comfort.

• Market for injectable drugs and isolator technology remains robust, with strong order pipeline and win rates above 40%.

• Expansion of US operations under review to address trade policy changes.